ArticleScience advances2025
Dual-phoretic wireless device for directionally oriented and carrier-free targeted drug delivery.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biointegrated Battery-Based Electroceuticals.Advanced materials (Deerfield Beach, Fla.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug localization, release control, and penetration into solid tissues through biological tight junctions are crucial for the treatment of localized diseases with biological barriers by maximizing therapeutic efficacy of the drug and minimizing damage to normal organs. Here, we introduce a dual-phoretic wireless drug delivery system that harnesses the physical control of ion transportation: electrophoresis for controllable release and iontophoresis for directional penetration. Adjustable, pulsatile, and repeatable drug release under biological conditions is achieved using ion diodes and Zn-based electrochemical cells. Through seamless integration with iontophoretic compartments, a fourfold improvement in delivery efficiency compared to drug diffusion, reaching the core of in vivo tumor, is verified by a 3D tomographic analysis. Fully implantable and wireless operation in a simulated 2-week therapeutic scenario results in a remarkable 50% tumor reduction from the initial volume while minimizing damage to nearby normal tissue and off-target organs such as the heart, liver, spleen, and kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.